Emodin inhibits breast cancer metastasis by reducing lipid synthesis through the downregulation of triglyceride synthesis-related genes, including Fas, glycerol-3-phosphate acyltransferase 1 (Gpat1), and stearoyl-CoA desaturase 1 (Scd1). Here, SCD is linked to breast cancer.